Cytori Cell Research Institute, Inc. (3750) AI Stock Analysis

• Market Cap: ¥8.04B
• Dividend Yield: N/A
• Average Volume (3M): 9.19K
• Price to Earnings (P/E): 55.1
• Beta (1Y): 0.50
• Revenue Growth: -92.17%
• EPS Growth: -1648.96%
• Country: JP
• Employees: 16
• Sector: Healthcare
• Sector Strength: 39
• Industry: Biotechnology
• EPS (TTM): -155.53
• Shares Outstanding: 8,929,419
• 10 Day Avg. Volume: 16,260
• 30 Day Avg. Volume: 9,190
• PEG Ratio: 0.69
• Price to Book (P/B): 2.92
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 54 Neutral
• Price Target: ¥827.00 ▼(-8.11%Downside)

Cytori Cell Research Institute's score is primarily driven by its weak financial performance, reflecting significant profitability and liquidity challenges, along with a concerning valuation due to negative earnings. Despite these issues, the stock's strong technical indicators suggest short-term bullish momentum, which partially offsets the financial weaknesses. The absence of earnings call insights and corporate events further underscores the need for financial improvement.

Cytori Cell Research Institute, Inc. Business Overview & Revenue Model

Company Description

Cytori Cell Research Institute, Inc. (3750) is a biotechnology company specializing in the research and development of cell-based therapies. The company focuses on leveraging regenerative medicine techniques to address various medical conditions, primarily through the use of adipose-derived stem and regenerative cells. By harnessing the potential of these cells, Cytori aims to develop innovative treatments that can improve patient outcomes in areas such as cardiovascular disease, orthopedics, and wound care.

How the Company Makes Money

Cytori Cell Research Institute, Inc. generates revenue through the development and commercialization of its proprietary cell therapy technologies. The company primarily earns income by partnering with healthcare institutions and research organizations to conduct clinical trials and develop new therapeutic applications for its cell-based products. Additionally, Cytori may engage in licensing agreements with other biotechnology firms and pharmaceutical companies, receiving royalties and milestone payments for the use of its technologies. The company might also explore opportunities for government grants and funding to support its research initiatives, as well as direct sales of its therapeutic products once they receive regulatory approval.

Cytori Cell Research Institute, Inc. Financial Statement Overview

Summary

Cytori Cell Research Institute, Inc. exhibits concerning financial metrics across income, balance sheet, and cash flow statements. Revenue volatility and persistent negative earnings signal operational challenges. The high leverage indicates financial risk, while negative cash flow points to potential liquidity issues. Strategic improvements are necessary to enhance financial stability and growth potential.

Income Statement

The company's revenue has demonstrated inconsistency over the years, with a significant decrease in the most recent TTM. Gross profit margins are moderate, but the persistent negative EBIT and net incomes indicate challenges in achieving profitability. The declining revenue trend and negative margins highlight a need for strategic adjustments to improve profitability.

Balance Sheet

The company maintains a substantial amount of stockholders' equity, which positively impacts the equity ratio. However, the debt-to-equity ratio is concerning, with total debt levels consistently high relative to equity. This highlights potential financial risk due to high leverage. Stability in equity levels is a positive aspect, but the high debt burden remains a significant concern.

Cash Flow

The cash flow statements reveal a troubling lack of positive free cash flow in recent periods, with operating cash flow often negative. This indicates challenges in generating cash from operations, crucial for sustaining business activities. The free cash flow to net income ratio is not supportive of strong liquidity, suggesting potential cash management issues.

Breakdown	TTM	Mar 2024	Mar 2023	Mar 2022	Mar 2021	Mar 2020
Income Statement
Total Revenue	263.80M	1.56B	2.14B	1.34B	1.39B	1.18B
Gross Profit	129.64M	1.29B	1.27B	859.23M	760.32M	756.00M
EBITDA	-906.82M	-603.09M	-705.34M	348.90M	-261.86M	43.00M
Net Income	-60.21M	138.16M	-1.06B	-77.63M	-831.86M	319.00M
Balance Sheet
Total Assets	4.89B	5.82B	14.09B	16.01B	14.92B	15.48B
Cash, Cash Equivalents and Short-Term Investments	443.00M	1.04B	1.12B	851.56M	1.07B	999.00M
Total Debt	2.66B	2.47B	8.51B	9.27B	8.53B	8.77B
Total Liabilities	2.87B	3.02B	11.43B	12.29B	11.38B	11.65B
Stockholders Equity	2.02B	2.79B	2.65B	3.71B	3.55B	3.81B
Cash Flow
Free Cash Flow	0.00	-1.17B	-198.04M	-367.83M	-98.86M	531.00M
Operating Cash Flow	0.00	-1.15B	-39.52M	-187.78M	-82.90M	531.00M
Investing Cash Flow	0.00	8.69B	-283.06M	-216.19M	6.70M	-7.42B
Financing Cash Flow	0.00	-7.17B	294.23M	35.80M	150.65M	6.36B

Cytori Cell Research Institute, Inc. Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 900.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3750, the sentiment is Positive. The current price of 900 is above the 20-day moving average (MA) of 746.60, above the 50-day MA of 709.34, and above the 200-day MA of 821.85, indicating a bullish trend. The MACD of 33.05 indicates Negative momentum. The RSI at 84.16 is Negative, neither overbought nor oversold. The STOCH value of 93.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JP:3750.

Cytori Cell Research Institute, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	¥342.56B	10.47	-2.86%	2.57%	11.81%	-7.17%
3750	54 Neutral	¥8.04B	55.07		―	-92.17%	-1648.96%
4884	54 Neutral	¥5.65B	―		―	12.66%	24.73%
4564	47 Neutral	€8.23B	―	-148.36%	―	22.93%	47.73%
4576	46 Neutral	¥5.31B	―	-113.58%	―	4.59%	9.71%
4591	37 Underperform	¥4.37B	―		―	-96.64%	8.92%
4598	28 Underperform	¥7.64B	―		―	―	-11.46%